What Is Retatrutide? How Does It Work, and Is It Legal?

Ever since Ozempic entered the market in 2018 to treat diabetes, the GLP-1 market has exploded. In less than a decade, new therapies have been introduced, including Wegovy, Tirzepatide, and now retatrutide.

What's fascinating is these aren't simply reformulations or slow-release versions of existing drugs. Instead, each new therapy builds upon the last by adding another mechanism of action. Ozempic and Wegovy have one, Tirzepatide has two, and retatrutide has three.

These three mechanisms make retatrutide the most potent GLP-1 therapy currently in development, and the most potent. This article explains how it works, why it's different, and where it currently stands legally.

What Is Retatrutide?

Retatrutide, also known as "Reta," is a next-generation GLP-1 medication being developed by Eli Lilly to treat obesity. It's currently undergoing Phase 3 clinical trials, so it's not yet fully FDA-approved for commercial prescription or public use. Yet.

From the studies and trials we have, Reta is producing very promising results with significant weight loss and no significant side effects. As such, if everything continues to run smoothly, it will likely reach shelves by late 2027.

How Does Retatrutide Work?

Retatrutide stands out from other GLP-1s as it works on three hormone receptors instead of just one (Semaglutide/WeGovy) or two (Tirzepatide/Mounjaro & Zepbound).

• GLP-1: Decreases appetite and slows stomach emptying.
• GIP: Enhances insulin response and improves nutrient management.
• Glucagon: Enhances insulin response and improves nutrient management.

Theoretically, this makes it a stronger compound as it targets the mechanisms of weight gain through more pathways. And from the data we currently have, it seems to be true.

1. GLP-1 Activation helps regulate appetite and blood sugar. It acts on the brain to increase feelings of fullness, slows stomach emptying to help you stay satisfied after meals, and signals the pancreas to release insulin when blood sugar levels rise.

2. GIP Activation helps regulate blood sugar by increasing insulin release after meals. When combined with GLP-1, it appears to enhance glucose control and may improve tolerability, allowing higher therapeutic doses with fewer gastrointestinal side effects in many people.

3. Glucagon Activation signals the liver to release stored energy and increase fat burning. By accelerating fat oxidation in the liver, it may help raise the body's metabolic output to enhance overall calorie expenditure. When balanced properly, this process effectively mobilizes stored reserves to promote weight loss.

Retatrutide Vs. Ozempic Vs. WeGovy Vs. Tirzepatide

The primary difference between Retarditude and other GLP-1s comes down to it being a triple agonist. Unlike previous GLP-1s that worked on one or two hormone receptors, Retarditude works on three.

• Ozempic- 1 // GLP-1
• WeGovy- 1 // GLP-1
• Tirzeptide- 2 // GLP-1 / GIP
• Retatrutide- 3 // GLP-1 / GIP / Glucagon

This additional mechanism results in several other differences, such as dosing and effectiveness. 

Primary Purpose and Dosing

Retatrutide is being developed to specifically treat weight loss, but this is not true for all other GLP-1 medications. This list compares their: 

• Medication: Primary Use // Frequency // Starting Dose // Maximum Amount
• Ozempic: Type 2 Diabetes //  Once Weekly  // 0.25 mg  // 2.0 mg
• Wegovy: Weight Loss // Once Weekly // 0.25 mg // 2.4 mg up to 7.2 mg*
• Tirzepatide(Mounjaro / Zepbound): Diabetes & Weight Loss // Once Weekly // 2.5 mg // 15.0 mg
• Retatrutide(Phase 3 Trials): Weight Loss (Investigational) // Once Weekly // 2.0 mg // 12.0 mg

Effectivness 

Comparing data from Retatrutide clinical trials shows it to be significantly more effective for weight loss when compared to previous GLP-1 medications. "//" separates results from different trials)

• Wegovy (Semaglutide)- 14.9% over 68 weeks
• Mounjaro/ZepBound  (Tirzeptide)- 15-21% //  25% over 72-88 weeks
• Retatrutide- 24.2% //  28% to 30% over 48 to 68+ weeks

First, it should be noted that they are all very effective. With that said, Retatrutide clearly shows the best results.

Tirzepatide is the closest competitor, producing about 25% weight loss over 88 weeks. Retatrutide reached that milestone in just 48 weeks and has since surpassed it, with Phase III trials still underway.

For perspective, losing 28–30% of your body weight over 10 months would roughly look like this:

• Starting weight: 170 lb → 120 lb
• Starting weight: 200 lb → 140 lb
• Starting weight: 250 lb → 175 lb
• Starting weight: 300 lb → 210 lb

That's significant and why some people even question if it's "too strong".

Side Effects

Similar to existing GLP-1 drugs, the primary side effects are gastrointestinal.

• Nausea
• Diarrhea
• Vomiting
• Constipation

It should be understood that there is no long-term data, as even Ozempic has only been on the market for about 8 years. The long-term effects of manipulating the targeted receptors aren't known, and there are some serious reports.

Is Retatrutide Legal?

Retatrutide is currently undergoing Phase III clinical trials and has not yet received FDA approval. As a result, healthcare providers cannot routinely prescribe it as an FDA-approved medication.

However, that does not automatically make retatrutide "illegal." Instead, it currently exists in a regulatory gray area. 

• Cannot be prescribed → Can be legally studied in approved clinical trials
• Cannot be sold for "human use" → Can be sold and marketed as "research chemicals." 
• Cannot buy at the store → Can buy online as "research chemicals"

Now you can see why it's called a "grey" area. 

Even though it's not FDA-approved yet, various online vendors can purchase Retatrutide from various unregulated labs. 

Since vendors aren't allowed to market retatrutide for human use, they label it as a "Research Chemical" and "Not for Human Use." Many even require you to acknowledge that you're purchasing it strictly for research purposes.

Let's be honest, though. It's unlikely that thousands of people suddenly developed a passion to conduct research with Reta or other peptides. 

Everyone understands why these products are being purchased, which makes the legal question difficult to answer. 

Is Using Retatrutide Safe?

Until Retatrutide is FDA-approved to be produced in regulated labs and pharmacies, there will be an increased risk. However, the risk isn't necessarily from Retatrutide itself but rather Retatrutide being developed in unregulated labs, which increases the risk of:

• Increased risk of contamination 
• Inactive

Remember that Retatrutide is currently going through Phase III trials. To get this far means it's already shown considerable safe use.

The Trials Of Retatrutide

When a new drug is brought to the market, it must go through a series of extensive human trials.  Each phase has a specific purpose that they try to elaborate on.

• Pre-Clinical Trials: Laboratory and animal studies used to evaluate safety and justify testing in humans.
• Phase 1 (Safety & Dosage): Tests safety, side effects, and appropriate dosage in a small group of participants (20–100).
• Phase 2 (Effectiveness): Evaluates how well the drug works while continuing to monitor safety in 100–300 patients with the target condition.
• Phase 3 (Confirmation): Confirms effectiveness, compares the drug to existing treatments or placebo, and monitors safety in 1,000–3,000 patients. These data are used for regulatory approval.
• Phase 4 (Post-Marketing): Monitors long-term safety, effectiveness, and rare side effects after the drug reaches the market.

We have a full summary of all the major pre-clinical studies and trials below, but as Reta is in Phase III, it's clear that:

• It showed significant benefit and low safety risk during pre-clinical trials to justify clinical trials.
• In Phases I and II, Reta proved to be safe and effective, and it was moved to Phase III.
• Even though it's still in Phase III, the data that has come out shows it is very promising.

When Will Retatrutide Be Available To The Public?

Unless something dramatic happens, all signs are pointing to Retatrutide passing Phase III trials. However, passing Phase III trials doesn't automatically give it FDA approval.

Therefore, assuming Reta passes, here's an approximate timeline and processes that must occur before it's available to the public.

• Complete Phase III Trials (Late 2026)- Remaining Phase III TRIUMPH trials are expected to finish, and final data will be analyzed.
• Submit a New Drug Application (NDA): Eli Lilly is expected to submit a New Drug Application (NDA) to the FDA for obesity if the Phase III program is successful.
• FDA Filing Review (~60 Days Later): The FDA determines whether to accept the application for formal review and assigns a target decision date (PDUFA).
• FDA Review (6–10 months) – Scientists review the clinical data, manufacturing process, labeling, and overall risk-benefit profile. Priority review is about 6 months; standard review is typically about 10 months.
• FDA Decision (approx. Mid– to Late–2027): If approved, retatrutide could receive FDA approval.
• Commercial Launch (Late 2027–Early 2028): Commercial availability is expected, depending on manufacturing and supply.

FAQ: What Is Retatrutide?

What is retatrutide?

Retatrutide is an investigational weight loss medication developed by Eli Lilly. Unlike Ozempic (GLP-1) or Tirzepatide (GLP-1/GIP), retatrutide activates three hormone receptors: GLP-1, GIP, and glucagon. It is currently undergoing Phase 3 clinical trials and has not yet received FDA approval.

How does retatrutide work?

Retatrutide works by activating three hormone receptors involved in appetite, blood sugar, and energy metabolism. GLP-1 reduces appetite and slows stomach emptying, GIP improves insulin response, and glucagon increases fat oxidation and energy expenditure. Together, these mechanisms produce greater weight loss than previous GLP-1 medications.

Is retatrutide legal?

Retatrutide is not currently FDA-approved and cannot be prescribed as an approved medication. It is legally available only through authorized clinical trials. Some companies sell it online as a "research chemical," but these products are not approved for human use and are not subject to the same manufacturing standards as prescription medications.

Is retatrutide FDA approved?

No. Retatrutide is currently in Phase 3 clinical trials and has not yet received FDA approval. If ongoing trials continue to demonstrate safety and effectiveness, regulatory approval could occur after the completion of these studies.

Is retatrutide more effective than Ozempic or Tirzepatide?

Current clinical trials suggest retatrutide produces greater average weight loss than both semaglutide (Ozempic/Wegovy) and Tirzepatide. While semaglutide produces about 15% weight loss and Tirzepatide about 20–25% in clinical trials, retatrutide has demonstrated weight loss approaching 30% in ongoing studies.

What are the side effects of retatrutide?

The most common side effects are gastrointestinal and include nausea, vomiting, diarrhea, constipation, and stomach discomfort. These side effects are similar to those reported with other GLP-1 medications and are generally more common during dose escalation.

When will retatrutide be available?

Retatrutide is still being evaluated in Phase 3 clinical trials. Although no official approval date has been announced, many industry analysts expect it could become available after successful completion of these trials and FDA review, potentially in 2027.

Retatrutide Trials - The Nitty Gritty

Pre-Clinical Trials

Coskun et al. (2022) – From Discovery to Clinical Proof of Concept

Study Design: Drug discovery and preclinical development study combining laboratory, animal, and early translational human research.

Major Findings:

• Developed LY3437943 (retatrutide), a novel triple agonist targeting the GLP-1, GIP, and glucagon receptors.
• Demonstrated potent activation of all three receptors.
• Animal studies showed greater weight loss, improved glucose control, and increased energy expenditure compared with existing incretin therapies.
• Early human proof-of-concept findings supported advancement into dedicated clinical trials.

Phase 1 Trials Of Retatrutide

Urva et al. (2022, The Lancet)

Study Design: Phase 1b, proof-of-concept, double-blind, placebo-controlled, randomized, multiple-ascending-dose trial in adults with type 2 diabetes.

Major Findings:

• Demonstrated an acceptable safety and tolerability profile.
• Supported once-weekly dosing based on pharmacokinetic findings.
• Produced clinically meaningful reductions in HbA1c and body weight.
• Gastrointestinal events were the most common adverse effects and were generally consistent with other incretin-based therapies.

Phase 2 Trials Of Retatrutide

Jastreboff et al. (2023, New England Journal of Medicine) – Obesity Trial

Study Design: Randomized, double-blind, placebo-controlled Phase 2 trial in adults with obesity or overweight.

Major Findings:

• Produced substantial dose-dependent weight loss, with the highest dose achieving approximately 24% mean weight loss at 48 weeks.
• Significant improvements in waist circumference and multiple cardiometabolic risk factors.
• Gastrointestinal adverse events were the most common side effects and were generally mild to moderate.

Rosenstock et al. (2023, The Lancet) – Type 2 Diabetes Trial

Study Design: Randomized, double-blind, placebo- and active-controlled Phase 2 trial in adults with type 2 diabetes.

Major Findings:

• Produced significant dose-dependent reductions in HbA1c.
• Produced substantial body weight loss across treatment groups.
• Demonstrated an acceptable safety profile, with gastrointestinal events being the most frequently reported adverse effects.

Sanyal et al. (2024) – MASLD/Liver Fat Substudy

Study Design: Substudy evaluating liver fat and metabolic dysfunction-associated steatotic liver disease (MASLD) in participants receiving retatrutide.

Major Findings:

• Significantly reduced liver fat content.
• Many participants achieved normalization of liver fat levels.
• Improvements in liver enzymes accompanied reductions in body weight.

Body Composition DXA Substudy (2025)

Study Design: DXA imaging substudy of participants from the Phase 2 type 2 diabetes trial evaluating changes in fat and lean mass.

Major Findings:

• The majority of weight loss resulted from reductions in fat mass rather than lean mass.
• Produced significant dose-dependent reductions in total body fat.
• Demonstrated favorable body composition changes while maintaining an acceptable safety profile.

Phase 3

Ramsbacher N. (2024, Clinical Diabetes)

Study Design: Narrative review summarizing the ongoing Phase 3 clinical development program.

Major Findings:

• Reviewed the design and rationale of the TRIUMPH and TRANSCEND clinical trial programs.
• Discussed retatrutide's potential role in obesity, type 2 diabetes, and related metabolic diseases.

TRIUMPH Program – Phase 3 Obesity Trials

Study Design: Global Phase 3 randomized clinical trial program evaluating retatrutide in adults with obesity or overweight.

Primary Outcomes:

• Percentage change in body weight.
• Proportion of participants achieving clinically meaningful weight-loss milestones.
• Long-term safety and tolerability.

TRANSCEND Program – Phase 3 Type 2 Diabetes Trials

Study Design: Global Phase 3 randomized clinical trial program evaluating retatrutide in adults with type 2 diabetes.

Primary Outcomes:

• Change in HbA1c.
• Change in body weight.
• Long-term safety, tolerability, and cardiovascular risk factors.

References

1. Abdrabou Abouelmagd, A., Abdelrehim, A. M., Bashir, M. N., Abdelsalam, F., Marey, A., Tanas, Y., … Belal, M. M. (2025). Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist for obesity treatment: a systematic review and meta-analysis of randomized controlled trials. Baylor University Medical Center Proceedings, 38(3), 291–303. https://doi.org/10.1080/08998280.2025.2456441
2. ClinicalTrials.gov. (2026). A study of retatrutide (LY3437943) compared with tirzepatide in participants who have obesity or overweight (TRIUMPH-5) (NCT06662383). U.S. National Library of Medicine. https://clinicaltrials.gov/study/NCT06662383
3. Coskun T, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metabolism, 34(9), 1234–1247.e9 (2022). https://www.thelancet.com/journals/landia/article/PIIS2213-8587(25)00092-0/abstract
4. Coskun, T., Wu, Q., Schloot, N. C., Haupt, A., Milicevic, Z., Khouli, C., & Harris, C. (2025). Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial. The lancet. Diabetes & endocrinology, 13(8), 674–684. https://doi.org/10.1016/S2213-8587(25)00092-0
5. Eli Lilly and Company. (2026, March 19). Lilly's triple agonist, retatrutide, demonstrated significant reductions in A1C and weight in first Phase 3 trial for treatment of type 2 diabetes. https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-demonstrated-significant
6. Jastreboff, A. M., Kaplan, L. M., Frías, J. P., Wu, Q., Du, Y., Gurbuz, S., Coskun, T., Haupt, A., Milicevic, Z., Hartman, M. L., & Retatrutide Phase 2 Obesity Trial Investigators (2023). Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. The New England journal of medicine, 389(6), 514–526. https://doi.org/10.1056/NEJMoa2301972
7. Rosenstock, J., Frias, J., Jastreboff, A. M., Du, Y., Lou, J., Gurbuz, S., Thomas, M. K., Hartman, M. L., Haupt, A., Milicevic, Z., & Coskun, T. (2023). Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet (London, England), 402(10401), 529–544. https://doi.org/10.1016/S0140-6736(23)01053-X
8. Sanyal, A. J., Kaplan, L. M., Frias, J. P., Brouwers, B., Wu, Q., Thomas, M. K., Harris, C., Schloot, N. C., Du, Y., Mather, K. J., Haupt, A., & Hartman, M. L. (2024). Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nature medicine, 30(7), 2037–2048. https://doi.org/10.1038/s41591-024-03018-2
9. Urva, S., Coskun, T., Loh, M. T., Du, Y., Thomas, M. K., Gurbuz, S., Haupt, A., Benson, C. T., Hernandez-Illas, M., D'Alessio, D. A., & Milicevic, Z. (2022). LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. Lancet (London, England), 400(10366), 1869–1881. https://doi.org/10.1016/S0140-6736(22)02033-5